Unlocking Hope: Masonic Cancer Center’s Groundbreaking Findings on HCW9218 for Solid Tumors at SITC 37th Annual Meeting
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation From the Phase 1 Clinical Trial to Evaluate HCW9218 Safety and Dosage Escalation The poster presentation will include data on safety and dosage escalation of HCW9218, a TGF-β trap developed by HCW Biologics Inc. Throughout the Phase 1 clinical trial, researchers have closely…